Horizon Pharma plc to Present at Three Conferences in November
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Guggenheim Shows Increasing Confidence in Horizon Pharma (HZNP) Following 3Q Beat; Reiterates Buy
November 6, 2015 11:10 AM ESTGuggenheim reiterated a Buy rating and $40.00 price target on Horizon Pharma (NASDAQ: HZNP) following the company's 3Q15 earnings report. HZNP reported adjusted diluted 3Q15 EPS of $0.70, $0.29 above consensus. The company also raised its '15 EBITDA guidance to $350MM-$360MM from $265MM-$280MM, consensus was... More
